SCHEMBL19125747

SCHEMBL19125747

ONc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OCCOC(F)F

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EGFR P00533 14/20 0.55
▸ ERBB2 P04626 8/20 0.49
▸ KDR P35968 10/20 0.48
▸ EPHB4 P54760 7/20 0.47
▸ EPHA2 P29317 6/20 0.47
▸ FLT1 P17948 5/20 0.47
▸ RIPK2 O43353 2/20 0.47
▸ RET P07949 2/20 0.47
▸ EPHB2 P29323 2/20 0.47
▸ EPHA4 P54764 2/20 0.47
▸ BTK Q06187 2/20 0.47
▸ RIPK3 Q9Y572 2/20 0.47
▸ GAK O14976 1/20 0.47
▸ EPHB6 O15197 1/20 0.47
▸ STK10 O94804 1/20 0.47
▸ MAP4K4 O95819 1/20 0.47
▸ ABL1 P00519 1/20 0.47
▸ LCK P06239 1/20 0.47
▸ YES1 P07947 1/20 0.47
▸ LYN P07948 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17967489 0.91 EGFR (0.57) EGFRERBB2KDREPHB4EPHA2
SCHEMBL20653156 0.89 EGFR (0.57) EGFRERBB2KDR
SCHEMBL18012884 0.88 EGFR (0.53) EGFRERBB2KDREPHB4EPHA2
SCHEMBL19100062 0.88 EGFR (0.53) EGFRERBB2KDREPHB4EPHA2
SCHEMBL18012086 0.87 EGFR (0.63) EGFRERBB2KDREPHB4EPHA2
SCHEMBL18012085 0.87 EGFR (0.63) EGFRERBB2KDREPHB4EPHA2
SCHEMBL19100075 0.86 EGFR (0.66) EGFRKDR
SCHEMBL19100462 0.84 EGFR (0.52) EGFRERBB2KDREPHB4EPHA2
SCHEMBL19100267 0.84 EGFR (0.61) EGFRERBB2KDR
SCHEMBL17967491 0.84 KDR (0.61) EGFRERBB2KDREPHB4EPHA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017117680-A1 NOVEL FLUORINATED QUINAZOLINE DERIVATIVES AS EGFR INHIBITORS TRILLIUM THERAPEUTICS INC. (CA) 2017-07-13 — — WO disclosed
Send feedback